TAK-003 Dengue Vaccine Administration in People with HIV, an Observational Study.

Authors

Nicolò Moschetta, Riccardo Lolatto, Nicolò Capra, Angelo Roberto Raccagni, Silvia Nozza, Monica Guffanti, Antonella Castagna, Giovanni Gaiera, Diana Canetti

Published in

The new microbiologica. Volume 49. Issue 2. Pages 145-149.

Abstract

With its rising incidence, dengue is a growing global health concern. This retrospective observational study evaluated short-term safety of the dengue vaccine TAK-003 in people with asymptomatic HIV infection and no evidence of impaired immune function that have received at least one dose of TAK-003 at the Travel Medicine Clinic of the Infectious Diseases Unit of San Raffaele Scientific Institute, Milan, Italy, from January 2024 to December 2025. Globally, 12/20 (60%) participants did not report any adverse event after both doses. Seven (35%) experienced mild general or local disorders after dose 1, one reported local disorders after D2. In each case, adverse events resolved spontaneously after 1-3 days. No severe AEs were reported. HIVRNA, CD4+ count and percentage did not significantly vary after both doses of TAK-003. TAK-003 was well tolerated, with adverse events being generally mild, self-limiting and comparable to those observed in the general population. Individuals of ≥60 years of age did not report any adverse events. No significant changes in HIVRNA, CD4+ count and percentage were observed after vaccination.

PMID:
42507126
Bibliographic data and abstract were imported from PubMed on 27 Jul 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.